GET DAILY SIGNALSAxsome Therapeutics (AXSM): Analyst Targets Suggest +94% Upside to $280
Key Takeaways
- The central stock price target of $280 is the arithmetic mean of the individual analyst price targets reviewed (roughly $278), consistent with the ~$277–$278 average reported across roughly 22 analysts.
- The latest verified price is around $144, so reaching $280 would require an upside of roughly 94% — a very large move by any conventional measure.
- The analyst target range is unusually wide, spanning from $238 (Piper Sandler) to $380 (Jefferies), signaling genuine disagreement about valuation.
- Supporting factors include rapid revenue growth from Auvelity, Sunosi and Symbravo, a newly approved Alzheimer's disease agitation indication, and a late-stage pipeline led by AXS-05.
- The biggest risks are persistent GAAP losses, a sharp pullback from mid-2026 highs, recent price-target cuts, and regulatory and competitive uncertainty.
- For more context, explore Major News, Today's Price Move, Forecast, and Earnings.
- For AI-driven trading ideas, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Axsome Therapeutics, Inc. (AXSM) is a biopharmaceutical company focused on central nervous system (CNS) disorders. Across roughly a dozen individually verified analyst targets — spanning Mizuho ($284), Truist ($285), H.C. Wainwright ($290), RBC Capital ($295), Needham ($268), Deutsche Bank ($267), Guggenheim ($275), UBS ($256), Wells Fargo ($256), Morgan Stanley ($247) and Piper Sandler ($238), up to Jefferies' street-high $380 — the arithmetic mean lands at about $278, which rounds to the $280 central target used here.
The full range is wide, from $238 to $380, and aggregators reporting on roughly 22 analysts show an average near $277–$278 with a "Strong Buy" bias. That dispersion matters: it reflects differing views on how fast Axsome's newer products can scale and whether its pipeline justifies a premium. Notably, several firms trimmed targets in October 2026 — Mizuho to $284 from $316, Piper Sandler to $238 from $258, Deutsche Bank to $267 from $280, and Morgan Stanley to $247 from $251 — while Jefferies' $380 stands well above the group. The $280 figure is a calculated average, not an official published consensus or a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Axsome shares traded near $144 at the end of October 2026, well below the all-time high of roughly $260 reached in June 2026. Reaching $280 from that level implies a gain of about 94%, which qualifies as a very large required move. In practical terms, the stock would first need to recover its recent pullback before making new highs.
Fundamentally, the company is growing quickly but remains unprofitable on a GAAP basis. Second-quarter revenue of roughly $218 million represented strong year-over-year growth of about 63%, and the launch of Auvelity for agitation associated with Alzheimer's disease and dementia has expanded its addressable market. A path toward the target would likely depend on sustained double-digit product growth, progress toward breakeven, and positive pipeline data, rather than a single catalyst.
What Could Support a Move Toward the Target
- Commercial momentum: Auvelity (depression and Alzheimer's disease agitation), Sunosi (excessive daytime sleepiness) and Symbravo (acute migraine) are ramping, with revenue growing at a roughly 63% annual pace.
- Expanded indications: The new dementia-related agitation approval for Auvelity materially widens the market opportunity.
- Late-stage pipeline: AXS-05 for Alzheimer's disease agitation, including the SUMMIT Phase 3 program, offers additional upside optionality.
- Constructive sell-side view: The overwhelmingly "Buy"/"Strong Buy" stance, with most targets well above the current price, reflects optimism about the CNS franchise.
What Could Prevent the Target From Being Reached
- Persistent losses: The company continues to post GAAP net losses, and profitability is not yet assured.
- Recent target cuts: Multiple firms lowered their targets in late 2026, signaling tempered near-term expectations.
- Sharp drawdown: A decline from the mid-2026 high near $260 to the mid-$140s suggests fragile investor sentiment.
- Regulatory and competitive risk: Labeling decisions, payer access, and competition in CNS and migraine markets could pressure growth assumptions.
Technical Levels and Market Structure
Axsome's all-time high near $260 (June 2026) now sits far above the current price, leaving a large overhead gap. After breaking below the $150 area, that level may now act as initial resistance, with the $200 round number and the prior peak near $260 representing longer-term hurdles. There is no verified nearby support zone beyond recent lows in the mid-$140s, which underscores the downside risk if selling pressure resumes.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual analysts may model different periods. Investors should watch the next quarterly earnings report and any guidance on revenue growth and the path to profitability, along with analyst target revisions and data readouts from the AXS-05 program. Updates on Auvelity's agitation launch, Symbravo adoption, and gross-to-net pricing trends will also be important inputs to the market outlook.
Using Tickeron AI for Daily Signals
From what I see, Tickeron's AI Daily Buy/Sell Signals provide a practical way to monitor names like Axsome Therapeutics, Inc. (AXSM) by generating Buy, Sell, or Hold signals based on technical behavior and market conditions. I’ve found it helpful for tracking shifts without constant manual review, especially when following a stock with this much analyst dispersion. The platform lets users compare AXSM’s signals against the broader market in a systematic way.
Final Assessment
The central $280 target — the average of the verified analyst targets reviewed — sits about 94% above Axsome's current price of roughly $144, a very large gap that reflects both the stock's sharp 2026 drawdown and analysts' longer-term optimism about its CNS franchise. The bull case rests on strong revenue growth, a new Alzheimer's agitation indication, and a promising pipeline, while the bear case points to ongoing losses, recent target reductions, and a wide $238-to-$380 target range that shows real disagreement. Whether AXSM can ultimately reach $280 depends on continued commercial execution and pipeline progress; the next earnings report and any AXS-05 updates will be the clearest near-term signals. I'm watching this closely as earnings approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AXSM in upward trend: price may jump up because it broke its lower Bollinger Band on October 23, 2026
AXSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 35 cases where AXSM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Bearish Trend Analysis
The 50-day moving average for AXSM moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for AXSM entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. AXSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AXSM's P/B Ratio (90.816) is slightly higher than the industry average of (3.162). P/E Ratio (-38.515) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (13.908) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services for pain and other nervous system
Industry Biotechnology
Advertisement